Clinical Sciences Core (Core C)
临床科学核心(核心 C)
基本信息
- 批准号:9322043
- 负责人:
- 金额:$ 28.47万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2007
- 资助国家:美国
- 起止时间:2007-06-01 至
- 项目状态:未结题
- 来源:
- 关键词:AIDS preventionAIDS/HIV problemAcquired Immunodeficiency SyndromeAreaAwardBehavioralBehavioral ResearchBiologicalBiometryCenters for Disease Control and Prevention (U.S.)ClinicalClinical ManagementClinical ResearchClinical SciencesClinical ServicesClinical TreatmentCollaborationsComplementConduct Clinical TrialsConsent FormsConsultationsDataData Base ManagementData CollectionData QualityDatabasesDrug IndustryExerciseFloridaFosteringGeographic LocationsGoalsGood Clinical PracticeGrantHIVHIV InfectionsHospitalsHuman ResourcesIndividualInstitutesLaboratoriesLeadershipLearningLife Cycle StagesManaged Care ProgramsManuscriptsMedicaidMentorsMethodologyMissionMonitorOutcomePatientsPilot ProjectsPlayPreventionProductivityPublicationsQuality ControlResearchResearch DesignResearch InfrastructureResearch PersonnelResearch PriorityResourcesRightsRoleSafetyScientistServicesSocial WelfareSpecimenStatistical Data InterpretationTrainingTraining and EducationTranslational ResearchUnited States Health Resources and Services AdministrationUnited States National Institutes of HealthUniversitiesWomanbaseclinical caredesignhuman datahuman subjectimprovedinnovationmultidisciplinarypreclinical studyprogramsprotocol developmentresearch facilityresponsesample collectionsocialsuccesssynergismtool
项目摘要
Clinical Sciences Core (C) Project Summary/Abstract
The Clinical Sciences Core (Core C) is led by Dr. Rafael Campo as Director, Drs. Charles Mitchell and Margaret
Fischl as Co- Directors, and Dr. David Ludwig as Biostatistical Subcore leader. During the past 4 years, Core C
provided essential services that both enhanced the productivity of new and established investigators and
fostered collaborative research among basic, translational, behavioral, social, and clinical scientists. Core C
provided support and services for over 70 projects supported by various NIH institutes and networks, the CDC,
the HRSA, and the pharmaceutical industry, as well as pilot awards. Among notable Core C successes, we have
added a second clinical research unit through synergistic interactions with diverse stakeholders and we have
identified large databases that will offer new avenues for research. The mission and goals of Core C are driven
by the research priorities of the Miami CFAR investigators, and the Core makes every possible effort to support
these needs in a manner that fosters synergy and collaboration between CFAR cores and investigators and
produces economies of scale and effort. The support provided by Core C is indispensable to our investigators in
general and to our young investigators in particular because, in many instances, this support would not be
available were it not for the existence of the CFAR. Specific aims are: Aim 1. Provide state-of-the-art facilities
for implementation of, clinical research and services including sample and data collection and to facilitate training
/education of junior investigators. Aim 2. Provide research design methodology and technical assistance to meet
regulatory standards in research that involves human subjects, human data, and biological specimens, and; Aim
3. Provide research design and biostatistical support through a CFAR Biostatistics Sub-core. Core C will serve
as a valuable resource that provides investigative tools and mentoring support beyond that which is available
through routine grant mechanisms.
临床科学核心(C)项目摘要/摘要
临床科学核心(核心C)由主任Rafael Campo博士、Charles Mitchell博士和Margaret博士领导。
Fischl担任联合董事,大卫路德维希博士担任生物统计子核心负责人。在过去的四年里,核心C
提供了基本服务,既提高了新设调查员和常设调查员的生产力,
促进基础、转化、行为、社会和临床科学家之间的合作研究。芯C
为70多个项目提供支持和服务,这些项目得到了NIH各研究所和网络、CDC、
HRSA和制药行业,以及试点奖。在核心C的显著成功中,我们有
通过与不同利益相关者的协同互动,增加了第二个临床研究单位,
确定了大型数据库,将提供新的研究途径。核心C的使命和目标是
由迈阿密CFAR调查人员的研究优先事项,核心尽一切努力支持
以促进CFAR核心和调查人员之间的协同作用和合作的方式满足这些需求,
产生规模经济和努力。Core C所提供的支持对我们的调查人员来说是不可或缺的,
一般来说,特别是对我们年轻的调查人员,因为在许多情况下,这种支持不会
如果没有CFAR的存在,具体目标是:目标1。提供最先进的设施
用于实施临床研究和服务,包括样本和数据收集,并促进培训
/初级研究人员的教育。目标2.提供研究设计方法和技术援助,
涉及人类受试者、人类数据和生物标本的研究中的监管标准;目的
3.通过CFAR生物统计子核心提供研究设计和生物统计支持。核心C将服务于
作为一个宝贵的资源,提供调查工具和指导支持超出了现有的
通过常规机制。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Rafael Eduardo Campo其他文献
Rafael Eduardo Campo的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Rafael Eduardo Campo', 18)}}的其他基金
True prevalence of pre-existing reverse transcriptase inhibitor resistance in tre
先前存在的逆转录酶抑制剂耐药性的真实流行率
- 批准号:
7336262 - 财政年份:2007
- 资助金额:
$ 28.47万 - 项目类别:
True prevalence of pre-existing reverse transcriptase inhibitor resistance in tre
先前存在的逆转录酶抑制剂耐药性的真实流行率
- 批准号:
7499044 - 财政年份:2007
- 资助金额:
$ 28.47万 - 项目类别: